HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Previous close
$2.40
Day range
$2.29 - $2.76
Year range
$1.87 - $4.20
Market cap
22.61M USD
Avg Volume
13.32K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.85M | -11.42% |
Net income | -4.72M | 12.53% |
Net profit margin | — | — |
Earnings per share | -0.55 | 15.38% |
EBITDA | -5.80M | 11.46% |
Effective tax rate | 16.92% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 25.83M | -40.41% |
Total assets | 28.98M | -39.92% |
Total liabilities | 3.88M | -29.43% |
Total equity | 25.10M | — |
Shares outstanding | 8.60M | — |
Price to book | 0.82 | — |
Return on assets | -45.69% | — |
Return on capital | -53.59% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -4.72M | 12.53% |
Cash from operations | -5.40M | 23.13% |
Cash from investing | 9.43M | 46.54% |
Cash from financing | -23.00K | 83.80% |
Net change in cash | 4.01M | 608.63% |
Free cash flow | -4.76M | 16.61% |
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
26
